Research interests: Motor control, tremor, gait initiation, gait disorders.
Enrollment Status: Closed
Primary Specific Aim: To compare the primary outcome as measured by the Schwab and England ADL (Parkinson's Disease functioning), PDQ-39, ambulatory capacity (sum of 5 UPDRS questions: falling, freezing, walking, gait, postural stability), Symbol Digit Modalities (cognitive impairment, and Modified Ranking value in the creatine group versus the placebo group against a background of dopaminergic therapy and best Parkinson's Disease care.
The research hypothesis is that the group being treated with creatine will show less disease progression by 5 years than the group as evaluated by a Global Statistical Test comprised of the above measures.
Enrollment Status: Active
Primary Study Objective: To assess the impact of pioglitzone on the progression of Parkinson's Disease in order to assess whether it is futile to proceed with further study of this agent. The progression of Parkinson's Disease will be measured by the change in total UPDRS score between the baseline visit and the 44 week visit (where baselineis after at least 8 weeks but no more than 8 months on 1 mg/day rasagiline or 10 mg/day of selegiline).
Secondary Study Objective: To collect additional efficacy and safety/tolerability data to be used in planning a subsequent Phase III trial of pioglitazone in early, treated Parkinson's Disease. Measures of cognition, mood, and blood and urine based biomarkers will also be explored.